Immune Microbubble Complex for Targeted Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods face challenges due to reduced efficacy caused by cancer cells producing interfering antibodies and systemic side effects, with existing treatments lacking a synergistic effect when used alone, especially in combination with ultrasound technology.
Innovation Solution
Development of an immune-microbubble complex comprising microbubbles conjugated with immune checkpoint inhibitory antibodies, which are activated by ultrasound sonophoresis to enhance immune response and target tumor cells, improving antibody delivery and therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If cancer immunotherapy agents are administered systemically, then therapeutic coverage is improved, but side effects and drug loss increase
Solution Approach 1:
The patent applies local quality by conjugating immunotherapy antibodies specifically to microbubbles that accumulate at the tumor site through ultrasound guidance. This ensures the therapeutic agent is delivered locally to the tumor rather than systemically, maintaining therapeutic coverage while minimizing exposure to healthy tissues and reducing side effects.
Solution Approach 2:
The patent uses microbubbles as an intermediary carrier to deliver immunotherapy antibodies to the tumor. The microbubbles serve as a mediator that transports the antibody from systemic circulation to the specific tumor location, enabling targeted delivery and reducing unnecessary systemic exposure.
2Ease of operation
If ultrasound is used alone for tumor treatment, then non-invasive treatment is achieved, but therapeutic effect is insufficient
Solution Approach 1:
The patent merges ultrasound technology with immunotherapy antibodies by conjugating the antibodies to microbubbles that are activated by ultrasound. This combination allows the non-invasive delivery method of ultrasound to carry the potent therapeutic effect of immunotherapy, achieving both ease of administration and reliable therapeutic outcome.
Solution Approach 2:
The patent creates a composite therapeutic system combining microbubbles (ultrasound-responsive) with immunotherapy antibodies. This composite structure allows the material to respond to ultrasound while delivering biological therapeutic agents, merging physical and biochemical therapeutic mechanisms.
3Adaptability or versatility
If cancer cells produce interfering antibodies, then immune response is modulated, but immunotherapy efficacy is reduced
Solution Approach 1:
The patent converts the harmful effect of cancer cells producing interfering antibodies into a benefit by using the same antibody production mechanism to deliver therapeutic antibodies. The conjugated antibodies on microbubbles are designed to overcome the interfering antibodies produced by cancer cells, turning the immune modulation challenge into an opportunity for targeted therapeutic delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immune-microbubble complex significantly increases anti-tumor effects and immune-enhancing effects when treated with high-intensity focused ultrasound, enhancing antibody delivery and immunotherapy efficacy while minimizing side effects.
Implementation Method 1
Microbubbles exposed to ultrasound cause cavitation which leads to temporary pore formation in the cell membrane of surrounding cells
Implementation Method 2
Microbubbles exposed to ultrasound cause cavitation
Implementation Method 3
an immune-microbubble complex comprising microbubbles; and an immune checkpoint inhibitory antibody conjugated on the surface of the microbubbles, which activates T cells by suppressing immune evasion of tumor cells in an environment in which an immune response is boosted by ultrasound sonophoresis
Data Source
AI summary
Provided is an immune microbubble complex, and a use thereof. An immune-microbubble complex (IMC) according to the presently claimed subject matter includes microbubbles to which an antibody is conjugated, in which the microbubbles have excellent stability and excellent antibody binding strength, and it was confirmed that, when the immune-microbubble complex is treated with high-intensity focused ultrasound (HIFU), an anti-tumor effect is significantly increased and an immune-enhancing effect is exhibited. Therefore, the immune-microbubble complex according to the presently claimed subject matter is expected to increase the efficiency of delivering the conjugated antibody and be used in both diagnosis and treatment of cancer, and exhibit various functions in the field of immunotherapy, including a contrast effect, half-life improvement, improved drug delivery, a lymphocyte concentration effect, cancer immunotherapy and induction of immunotherapy using ultrasound.